An article by Mohler and Pantuck, published on line last week in the Journal of Urology, provides two perspectives on the future potential of abiraterone acetate in the treatment of prostate cancer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, androgens, castration-resistant, CRPC, intermittent, mechanism of action, metastatic, trials | 12 Comments »
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
THE "NEW" PROSTATE CANCER INFOLINK